经颅磁刺激(TMS)治疗多发性硬化症抑郁症的可接受性和可行性
The goal of this single-arm, observational pilot study is to learn about the safety, feasibility, preliminary efficacy of TMS for the treatment of depression in people with MS. Participants will receive outpatient TMS treatment over the course of 5-6 weeks. Participants will complete validated questionnaires and exams before, during, and after treatment.
研究概览
详细说明
Multiple sclerosis (MS) is a chronic, immune-mediated disease of the central nervous system. Depression, or major depressive disorder, is highly prevalent in people with MS and often has a serious impact on quality of life. MDD can be difficult to treat with medications in MS. Transcranial magnetic stimulation (TMS) is a safe and approved treatment for treatment-resistant depression in the general population. However, little is known about the use of TMS for MDD in people with MS. This pilot study will evaluate the safety, feasibility, and preliminary efficacy of TMS for MDD in MS. Participants will receive outpatient neuronavigated-TMS for MDD. Various measures of MS and MDD symptoms will be monitored over the course of treatment. Clinical brain imaging will also be compared before and after TMS.
研究类型
联系人和位置
学习地点
-
-
Utah
-
Salt Lake City、Utah、美国、84108
- University of Utah Health
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
Adults diagnosed with MDD and MS who are eligible for TMS
描述
Inclusion Criteria:
- Established diagnosis of multiple sclerosis (any subtype) by 2017 McDonald criteria
- Established diagnosis of major depressive disorder (MDD) by DSM-5 criteria
- Eligible for transcranial magnetic stimulation (rTMS) for depression
Exclusion Criteria:
- MS relapse and/or steroid use within 3 months
- Active suicidal ideation
- History of seizure/epilepsy, brain tumor, or stroke
- History of bipolar disorder or psychosis
- Currently or planning to become pregnant
学习计划
研究是如何设计的?
设计细节
- 观测模型:CASE_ONLY
- 时间观点:PROSPECTIVE
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
TMS 治疗 MDD 的可行性,每位参与者的保留率。
大体时间:10周
|
10周
|
|
安全性和耐受性,通过治疗过程中的副作用和不良事件进行评估。
大体时间:10周
|
10周
|
次要结果测量
结果测量 |
大体时间 |
|---|---|
|
将使用治疗前后的 MADRS 评分来衡量抑郁反应率(症状减轻 50%)。
大体时间:10周
|
10周
|
|
抑郁缓解率将使用治疗前后的 MADRS 评分来衡量。
大体时间:10周
|
10周
|
|
将比较治疗前后 MRI 上的 MS 病变负担,以确定 TMS 对白质疾病负担的影响。
大体时间:1年
|
1年
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.